Not Too Early To Consider Funding For, Distribution Of Malaria Vaccine

In this Huffington Post opinion piece, Orin Levine, executive director of the International Vaccine Access Center at Johns Hopkins University, notes some of the parallels between the development of RTS,S, the experimental malaria vaccine currently being tested in Africa, and the polio vaccine, but he says “there are also some particularly disappointing ways in which the polio and malaria efforts could differ.”

Shortly after the success of the polio vaccine was announced in 1955, it “was licensed, … multiple manufacturers immediately lined up to produce the vaccine,” and “the U.S. government stepped up to pay for the vaccine,” Levine writes. The malaria vaccine’s “latest achievement should serve as an early signal for all parties to begin working earnestly to anticipate and overcome vaccine access issues,” he says, adding that “donors need to decide how their support will be used to fund this vaccine,” such as through the GAVI Alliance, and “the manufacturer and the buyers (whomever is chosen) need to begin discussions about pricing and volumes of vaccine now — and need to move toward making development and purchasing commitments” (10/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.